The purpose of the study is to study the safety of the combination of ranibizumab and MMC vs
monotherapy MMC vs intravitreal ranibizumab injection in patients with glaucoma.
A common problem after undergoing trabeculectomy surgery to create a bleb (blister or
bubble) to reduce intraocular pressure, is scarring of the opening. This scarring prevents
fluid drainage and interferes with the proper functioning of the bleb. MMC (Mitomycin C) is
usually administered intraoperatively, to reduce scarring and increase filtration. However,
the failure rate of trabeculectomy remains high. Anti-VEGF agents have been used
successfully in cases requiring bleb needling. The purpose of the study is to determine the
safety of the combination of ranibizumab and MMC vs monotherapy MMC in patients with
This is an open-label, Phase I/II safety study of 30 patients randomized to either treatment
with ranibizumab 0.5 mg intravitreally injected (n=10), combination ranibizumab 0.5mg
intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10) or
MMC therapy alone (n=10).
For the ranibizumab groups, a repeat injection of ranibizumab 0.5mg may be given PRN at 1
month if hypervascularity or neovascularization of the conjunctiva exists.
- undergoing trabeculectomy
- 21 years of age or older
- pregnancy or lactation
- any condition the investigator believes would impose a significant hazard to the
patient if investigational therapy were initiated
- history of ocular surface disease
- cataract surgery in the past 6 months
- history of active inflammatory, infectious or idiopathic keratitis